Catching you up on the week of November 17–23, 2025: the trial milestones, regulatory moves, and business developments shaping psychedelic medicine right now.
Bright Minds Biosciences Inc. (DRUG): Bright Minds expands scientific advisory board to support BMB-101 and new Prader-Willi program
Bright Minds Biosciences announced four additions to its scientific advisory board to support clinical development of its selective 5-HT2C agonist BMB-101 and newly nominated candidate BMB-105, including its recently launched Prader-Willi syndrome (PWS) program. The move followed the company's early-November initiation of a Phase 2a NOVA study and positioned it ahead of key epilepsy and neurodevelopmental data readouts anticipated in early 2026.
Source: stocktitan.net
Mind Medicine (MindMed) Inc. (MNMD): MindMed presents at Jefferies Global Healthcare Conference amid MM120 Phase 3 push
MindMed management presented at the Jefferies Global Healthcare Conference in London, part of a run of investor appearances (Stifel, Jefferies, Evercore and Piper Sandler) through November and December. The company reiterated that its pivotal Phase 3 trials of MM120 (lysergide) in generalized anxiety disorder and major depressive disorder remained on track, with topline readouts expected across 2026 and roughly $209 million in cash following an October raise.
Source: businesswire.com
That's the recap. Follow the Psychedelic Invest Index for how the sector is trading, and check back next week for the next edition.